Seattle biotech startup secures $11.2M to make drugs for ‘undruggable’ disease targets
Talus Bioscience, a Seattle-based biotech, recently announced it has raised $11.2 million in venture capital funding to advance its drug discovery program for treatment-resistant diseases.
Specializing in biochemical analysis in living cells, Talus Bioscience’s innovations allow researchers to see how drugs interact with small proteins that regulate gene expression. This capability provides insights into abnormal gene expression, a common source of many diseases, including cancer.
Co-founders Alex Federation and Lindsay Pino, who are part of Life Science Washington’s WIN Mentoring Program, were inspired by other founder-led companies in Seattle when launching Talus in 2020. With this new round, the startup has now raised $19.7 million in venture funding and currently employs 17 people.